Clinical Trials Logo

Hermansky Pudlak Syndrome clinical trials

View clinical trials related to Hermansky Pudlak Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT04193592 Not yet recruiting - Clinical trials for Interstitial Lung Disease

Efficacy and Safety of Pirfenidone Treatment in HPS-ILD

PEARL
Start date: December 1, 2019
Phase: Phase 2
Study type: Interventional

This research study will explore the safety and efficacy of the drug, pirfenidone, in patients with a diagnosis of Hermansky-Pudlak Syndrome (HPS) who have an associated interstitial lung disease (ILD) over a planned period of 56 weeks.

NCT ID: NCT02368340 Completed - Clinical trials for Hermansky Pudlak Syndrome

A Longitudinal Study of Hermansky-Pudlak Syndrome Pulmonary Fibrosis

Start date: March 2015
Phase:
Study type: Observational

Hermansky-Pudlak Syndrome (HPS) is a rare genetic disease that is associated with oculocutaneous albinism, bleeding, granulomatous colitis, and pulmonary fibrosis in some subtypes, including HPS-1, HPS-2, and HPS-4. Pulmonary fibrosis causes shortness of breath and progressive decline in lung function. In HPS patients with at-risk subtypes, almost all adults eventually develop fatal pulmonary fibrosis unless they undergo lung transplantation. The purpose of this study is to identify the earliest measurable pulmonary disease activity in individuals at-risk for HPS pulmonary fibrosis. The study also aims to develop biomarkers that will aid in understanding of the causes of HPS pulmonary fibrosis and facilitate more rapid conduct of therapeutic trials in HPS patients with mild pulmonary disease in the future.